Novo launches Saxenda in US, sees more launches in 2015
(Reuters) – Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker.
The company has said previously it expects sales from the drug to eventually reach $1 billion a year.
It said in a statement on Wednesday it would launch Saxenda in other markets later this year.
Novo plans to use 500 of its 3,000-strong U.S. sales force to promote Saxenda, but has warned a ramp-up of sales would be slow.
Deputy Chief Executive Kaare Schultz told Reuters last month safety concerns over past weight-loss medicines as well as reimbursement issues meant it would take a while to get sales of Saxenda going.
Shares in Novo, by far the largest company in the Nordic region by market capitalization, were down 0.46 percent to 391.39 crowns at 0930 EDT.
They hit all-time highs last month on news the company would resubmit its Tresiba insulin to U.S. regulators for approval.
Source: Reuters Health